Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation (NASDAQ: BCPC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global specialty ingredient manufacturer. This SEC filings page aggregates those disclosures, including current reports on Form 8-K and, via EDGAR, the company’s annual reports on Form 10-K, quarterly reports on Form 10-Q and other required filings.
Recent Form 8-K filings show how Balchem uses current reports to furnish quarterly financial results. For example, the company has filed 8-Ks under Item 2.02, “Results of Operations and Financial Condition,” to attach press releases reporting net sales, segment earnings, adjusted EBITDA and free cash flow for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments. Another Form 8-K details the results of Balchem’s annual meeting of shareholders, including director elections, auditor ratification and advisory votes on executive compensation.
Through this page, users can access Balchem’s periodic reports, which typically include segment information, risk disclosures, accounting policies and other data relevant to its specialty ingredients, animal nutrition and specialty chemical activities. Filings related to governance matters, such as shareholder voting outcomes, are also available.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key segment trends and clarify items such as non-GAAP measures referenced in Balchem’s earnings releases. Real-time updates from EDGAR help users see new 10-K, 10-Q and 8-K filings as they are posted, while Form 4 and other ownership-related filings can be reviewed to monitor insider transactions. This combination of official documents and AI-assisted analysis allows investors and researchers to study Balchem’s regulatory history, financial reporting and governance practices in a structured and accessible way.
Balchem Corporation senior executive Job Leonard van Gunsteren reported multiple equity compensation transactions. On February 11, 2026, he received 430 shares of restricted stock that vest over three years and 1,345 common shares from vesting performance stock units for the 2023–2025 performance period.
To cover tax obligations upon vesting, 756 shares were withheld at $178.68 per share on February 11 and 58 shares were withheld at $177.49 per share on February 12. He was also granted 1,600 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three. After these transactions he directly owns 10,149 common shares and 1,600 stock options.
Reid Martin Luther reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 7,900 shares at a weighted average price of $178.57 per share. Following the reported transactions, holdings were 9,073 shares.
Harris Theodore L reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 62,743 shares at a weighted average price of $178.58 per share. Following the reported transactions, holdings were 91,373 shares.
BCPC senior executive Graham George reported equity awards from the company. As SVP and Chief R&D Officer, he received a grant of 700 shares of common stock at a price of $0, increasing his directly held common stock to 3,200 shares, plus 20 shares held indirectly through a 401(k) plan.
The filing also shows a stock option grant for 2,600 shares of common stock with an exercise price of $178.68 per share, expiring on 02/11/2036. The restricted stock vests over three years (25%, 25%, 50%), while the options vest 20% in year one, 40% in year two, and 40% in year three.
Backus William A. reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 4,889 shares at a weighted average price of $178.59 per share. Following the reported transactions, holdings were 6,736 shares.
BCPC senior vice president Frederic Boned reported new equity awards and related tax share withholdings. On February 11, he acquired 2,870 shares of restricted common stock and 2,247 common shares from performance stock units vesting for the 2023–2025 period.
To cover tax obligations, 1,151 of those vested shares were withheld at $178.68 per share on February 11 and an additional 203 shares were withheld at $177.49 per share on February 12. He was also granted stock options for 10,500 shares at a $178.68 exercise price, vesting over three years and expiring on February 11, 2036. After these transactions, he directly owned 8,978 common shares, plus 441 shares held indirectly in a 401(k) plan and 10,500 stock options.
BCPC senior vice president and Chief HR Officer Michael Brent Tignor reported multiple equity compensation transactions. On February 11, 2026, he acquired 1,200 shares of restricted common stock at $0, vesting over three years, and 1,929 shares from vested performance stock units for the 2023–2025 period, including 31 dividend equivalent shares.
To cover tax obligations on these vestings, 991 shares were withheld at $178.68 on February 11, 2026 and 165 shares were withheld at $177.49 on February 12, 2026. He also received a stock option for 4,400 shares at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three, expiring on February 11, 2036. Following these transactions he directly held 10,723 common shares, plus 1,456 shares indirectly through a 401(k) plan and 4,400 stock options.
BCPC executive Hatsuki Miyata, EVP, CLO & Secretary, reported several equity compensation transactions. On February 11, 2026, Miyata acquired 1,710 shares of common stock as restricted stock that vests over three years and 2,247 shares from performance stock units for the 2023–2025 period.
To cover related tax liabilities, 877 shares were withheld at $178.68 per share on February 11 and 181 shares were withheld at $177.49 per share on February 12. Miyata also received a grant of 6,300 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three.
After these transactions, Miyata directly held 8,745 common shares and indirectly held 487 shares through a 401(k) plan, in addition to the 6,300 stock options.
Balchem Corporation executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported multiple equity compensation transactions and related tax withholdings. On February 11, 2026 he acquired 3,610 shares of common stock as restricted stock and 4,718 shares from vested performance stock units at no cost, while 2,416 of those vested units were withheld to satisfy tax obligations. He also received a stock option grant for 13,200 shares at an exercise price of $178.68 per share, vesting 20% in year one, 40% in year two, and 40% in year three, expiring in 2036. Additional shares were withheld on February 12, 2026 to cover taxes on previously granted restricted shares. After these transactions, he directly held 27,926 common shares, plus 1,086 shares held indirectly in a 401(k) plan, along with 13,200 stock options.
Rigaud Olivier, a director of issuer BCPC, reported an award of restricted common stock. On February 11, 2026, he acquired 870 shares at $0 per share as a grant, increasing his directly held common stock to 2,390 shares after the transaction.
The footnote explains that this restricted stock will vest in the reporting person one year after the grant date, and remains subject to transfer restrictions under a Restricted Stock Grant Agreement between the issuer and the director.